ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products.

ANI Pharmaceuticals

Domain Not Resolving

Euro

HSTS

WordPress

Cloudflare CDN

Sitelinks Search Box

Cloudflare

Wordpress Plugins

jQuery CDN

PostalAddress Schema

Risk, Safety, Compliance

Elizabeth Powell

Chief Medical Officer

Mary Pao

Owner/Opperator

Megan Thompson

Senior Vice President, Finance and Chief Financial Officer

Stephen Carey

Owner

Thomas Anderson

Business Management

Thomas Haughey

CEO Office

Venus Olivia

Vice President, US Market Access

Bill Mroczka

Vice President of Regulatory Affairs

Ellen Connolly

Vice President Supply Chain

Eric Martin

Arthur Przybyl

Krista Davis

SVP, Chief Human Resources Officer

James G. Marken

Sr. Vice President, Operations

Patrick Walsh

Chairman Of The Board

Interim President and Chief Executive Officer

Vice President & CFO

Nikhil Lalwani

President and Chief Executive Officer

Bryce Istvan

Director of Strategy Planning

Midwestern US Acquired Companies With More Than 10 Employees

Great Lakes Companies With More Than $10M in Revenue (Top 10K)

Biotechnology Acquired Companies With Fewer Than 1000 Employees

Great Lakes Acquired Companies With More Than 10 Employees

ANI Pharmaceuticals is a specialty pharmaceuticals industry that develops, manufactures and markets top-quality prescription pharmaceuticals, made in the U.S.A. ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies.

Post-IPO Debt - ANI Pharmaceuticals

Post-IPO Equity - ANI Pharmaceuticals

Citizens Bank

Baudette

Minnesota

United States

North America

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution

ANI Pharmaceuticals, Alimera Sciences merger to close on September 16

Alimera Sciences plunges after it sues ANI Pharmaceuticals to close deal

Earnings call: ANI Pharmaceuticals reports strong Q2 growth, raises guidance

ANI Pharmaceuticals prices upsized $275M convertible senior notes offering

ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder

Kenya

Africa

Canada

Australia

Oceania

Philippines

Asia

HTML5

Fonts.com

Adobe Flash

Gravity Forms

Google Analytics

Google Fonts

Adobe Fonts

Office 365

GlobalSign

Google Tag Manager

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 30, 2024 1:25 PM	562ae145
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 30, 2024 1:25 PM	10b62816
crunchbase trigger	general	Oct 31, 2024 9:55 AM	61348294
crunchbase profile	general	Oct 31, 2024 12:11 PM	0c628dfe
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	147fb98f
peers	general	Sep 30, 2024 1:25 PM	5e38730f
news basic	general	Sep 30, 2024 1:25 PM	d6ade432
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ANIPHARMACEUTICALS

ANI Pharmaceuticals

Last Close

55.86

22/11 21:00

Market Cap

1.19B

Beta: -

Volume Today

127.69K

Avg: -